ABCC2 p.Trp1254Phe
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 20082599
[PubMed]
Jemnitz K et al: "ABCC2/Abcc2: a multispecific transporter with dominant excretory functions."
No.
Sentence
Comment
97
Mutant Predicted location Substrate Activity changes Reference Human MRP2 Δ1-188 TMD0 LTC4 ↓ Fernandez et al., 2002 K316A JC, TM6 GMF ↔ Ryu et al., 2000 K324A TM6 GMF ↓ Ryu et al., 2000 K329A TM6 GMF ↔ Ryu et al., 2000 R412G DJ IC MTX ↓ Hulot et al., 2005 W417I IC, TM7-TM8 E2-17βG ↓ Hirouchi et al., 2004 LTC4 ↓ DNP-SG ↓ H439A TM8 GMF ↔ Ryu et al., 2000 K483A IC, JM, TM9 GMF ↓ Ryu et al., 2000 K590A JC, TM11 GMF ↔ Ryu et al., 2000 S789F NBD1 E2-17βG ↓ Hirouchi et al., 2004 LTC4 ↓ DNP-SG ↓↓ R1023A EC, JM, TM13 GMF ↔ Ryu et al., 2000 H1042A TM13 GMF ↔ Ryu et al., 2000 R1100A JC, TM14 GMF ↔ Ryu et al., 2000 P1158A IC, JM, TM15 LTC4 ↓↓ Letourneau et al., 2007 E2-17βG ↔ MTX ↔ Table 1. continued on next page Mutant Predicted location Substrate Activity changes Reference I1173F DJ IC, TM15-16 LTC4 No act Keitel et al., 2003 E2-17βG No act R1210A EC, JC, TM16 GMF ↓↓ Ryu et al., 2000 R1230A TM16 GMF ↔ R1257A JC, TM17 GMF ↓↓ W1254A JC, TM17 E2-17βG ↓↓ Ito et al., 2001a W1254C ↓↓ W1254F ↔ W1254Y ↔ W1254A JC, TM17 LTC4 ↓↓ Ito et al., 2001b W1254C ↓↓↓ W1254F ↓↓ W1254Y ↓↓ W1254A JC, TM17 MTX ↓↓ Ito et al., 2001a W1254C ↓↓ W1254F ↓↓ W1254Y ↓↓↓ A1450T NBD2 E2-17βG ↓↓ Hirouchi et al., 2004 LTC4 ↓↓ DNP-SG ↓↓ Rat Mrp2 K308M IC, JM, TM6 TLC-S ↔ Ito et al., 2001b DNP-G ↑ LTC4 ↓ E3040G ↔ K320M TM6 TLC-S ↑ DNP-G ↑ LTC4 ↓ E3040G ↑ K325M TM6 TLC-S ↓* DNP-G ↓↓↓* LTC4 ↓↓↓* E3040G ↓ D329N TM6 TLC-S ↔ DNP-G ↓ LTC4 ↓↓↓* E3040G ↓ R586L TM11 TLC-S ↓ DNP-G ↓↓* LTC4 ↓↓* E3040G ↔ R1019M IC, JM, TM13 TLC-S ↔ DNP-G ↑* LTC4 ↔ E3040G ↔ R1096L TM14 TLC-S ↑ DNP-G ↑ LTC4 ↔ E3040G ↔ EC, extracellular; IC, intracellular; JC, near the cytosol in the membrane; JM, juxtamembrane; TLC-S, tauro-litocholate-sulfate; GMF, glutathione- methyl-fluorescein; ↑, activity over control>1.2; ↔, 1.2>activity over control>0.8; ↓, 0.8>activity over control>0.5; ↓↓, 0.5>activity over control>0.1; ↓↓↓, 0.1>activity over control.
X
ABCC2 p.Trp1254Phe 20082599:97:1238
status: NEWX
ABCC2 p.Trp1254Phe 20082599:97:1358
status: NEWX
ABCC2 p.Trp1254Phe 20082599:97:1485
status: NEW105 The W1254F mutation did not affect estradiol-17β-glucuronide (E2-17βG) transport, but almost completely erased LTC4 and methotrexate (MTX) transport by the protein (Ito et al., 2001a).
X
ABCC2 p.Trp1254Phe 20082599:105:4
status: NEW
PMID: 15280218
[PubMed]
Gerk PM et al: "Estradiol 3-glucuronide is transported by the multidrug resistance-associated protein 2 but does not activate the allosteric site bound by estradiol 17-glucuronide."
No.
Sentence
Comment
156
The W1254F MRP2 mutant retained E217G transport, but not leukotriene C4 or methotrexate transport.
X
ABCC2 p.Trp1254Phe 15280218:156:4
status: NEW
PMID: 12406647
[PubMed]
Suzuki H et al: "Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition."
No.
Sentence
Comment
125
Conservatively and glutathione conjugates into the isolated mem- substituted Trp1254Phe transports E 17bG, but not2 brane vesicles from Sf9 cells expressing mutant rat LTC or methotrexate, whereas highly conservative-4 MRP2 [109].
X
ABCC2 p.Trp1254Phe 12406647:125:77
status: NEW
PMID: 11500505
[PubMed]
Ito K et al: "Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity."
No.
Sentence
Comment
47
Mutagenesis was carried out using the TransformerTM kit (CLONTECH, Palo Alto, CA) according to the manufacturer`s instructions with the following sense mutagenic primers (substituted nucleotides are underlined): W1254A (5Ј-C- ACAAACCCTGAACGCTTCTGGTGAGGATGAC-3Ј), W1254C (5Ј-CAC- AAACCCTGAACTGTCTGGTGAGGATGAC-3Ј), W1254F (5Ј-CACAAA- CCCTGAACTTTCTGGTGAGGATGAC-3Ј), and W1254Y (5Ј-CACAAA- CCCTGAACTATCTGGTGAGGATGAC-3Ј).
X
ABCC2 p.Trp1254Phe 11500505:47:337
status: NEW74 These included nonconservative substitutions with a nonaromatic nonpolar amino acid (Ala; W1254A-MRP2) and a nonaromatic polar amino acid (Cys; W1254C-MRP2), as well as conservative substitutions with polar (Tyr; W1254Y-MRP2) and nonpolar (Phe; W1254F-MRP2) aromatic amino acids.
X
ABCC2 p.Trp1254Phe 11500505:74:245
status: NEW76 As shown in Fig. 1B, wild-type MRP2 and its four mutants (W1254A, W1254C, W1254Y, and W1254F) were all expressed in the HEK293T cells at comparable levels.
X
ABCC2 p.Trp1254Phe 11500505:76:86
status: NEW77 Mean values of expression levels from four to six independent transfections relative to wild-type MRP2 were W1254A, 1.1; W1254C, 0.9; W1254F, 0.9; W1254Y, 1.0, respectively (Fig. 1B).
X
ABCC2 p.Trp1254Phe 11500505:77:134
status: NEW81 However, E217betaG transport by the W1254Y-MRP2 and W1254F-MRP2 mutants was similar to that of wild-type MRP2, in marked contrast to the comparable conservatively substituted MRP1-Trp1246 mutants, which were inactive for transport of this substrate (40).
X
ABCC2 p.Trp1254Phe 11500505:81:52
status: NEW84 [3 H]E217betaG Transport by W1254F-MRP2 Is No Longer Inhibited by LTC4-It has been shown previously that LTC4 inhibits MRP2-mediated E217betaG transport (39, 44).
X
ABCC2 p.Trp1254Phe 11500505:84:28
status: NEW85 Consequently, to determine whether E217betaG transport by a mutant MRP2 protein that no longer transports LTC4 could still be inhibited by this cysteinyl leukotriene, [3 H]E217betaG transport by the W1254F-MRP2 mutant was examined.
X
ABCC2 p.Trp1254Phe 11500505:85:199
status: NEW87 In contrast, LTC4 had no significant effect on [3 H]E217betaG transport by W1254F-MRP2, indicating that the loss of LTC4 transport by this mutant is associated with a loss of binding of this substrate.
X
ABCC2 p.Trp1254Phe 11500505:87:75
status: NEW97 B, immunoblot of membrane vesicles prepared from HEK293T cells transfected with empty vector (pcDNA3.1(-)), wild-type (WT-MRP2) and mutant (W1254A, W1254C, W1254F, and W1254Y) MRP2 cDNAs.
X
ABCC2 p.Trp1254Phe 11500505:97:156
status: NEW103 A, [3 H]E217betaG uptake was measured in membrane vesicles prepared from HEK293T cells transfected with empty vector (pcDNA3.1(-); open bar), wild-type MRP2 (WT-MRP2; solid bar), and mutant (W1254A-MRP2, W1254C-MRP2, W1254F-MRP2, and W1254Y-MRP2; shaded bars) cDNA expression vectors.
X
ABCC2 p.Trp1254Phe 11500505:103:217
status: NEW106 The results shown are the means Ϯ S.D. of triplicate determinations in a single experiment, and similar results were obtained in a second experiment. relative levels of [3 H]MTX transport by the W1254A, W1254C, W1254F, and W1254Y mutants were 14, 14, 11, and 1%, respectively, of wild-type MRP2.
X
ABCC2 p.Trp1254Phe 11500505:106:218
status: NEW108 [3 H]E217betaG Transport by Wild-type MRP2, but Not W1254F-MRP2, Is Inhibited by MTX-It has previously been shown that MTX inhibits MRP2-mediated transport of the GSH-conjugated substrates, dinitrophenyl-glutathione and N-ethylma- leimide-glutathione (21, 24).
X
ABCC2 p.Trp1254Phe 11500505:108:52
status: NEW111 To determine whether E217betaG transport by mutant MRP2 proteins that no longer transport MTX remained inhibitable by this antifolate, [3 H]E217betaG transport in membrane vesicles prepared from cells expressing W1254F-MRP2 and W1254Y-MRP2 was examined.
X
ABCC2 p.Trp1254Phe 11500505:111:212
status: NEW112 In contrast to wild-type MRP2, MTX had no significant effect on [3 H]E217betaG transport by either W1254F-MRP2 or W1254Y-MRP2 at concentrations of either 500 or 1000 M MTX (Fig. 4B).
X
ABCC2 p.Trp1254Phe 11500505:112:99
status: NEW116 In addition, we observed that [3 H]E217betaG transport by the MRP2 mutants W1254A, W1254C, W1254F, and W1254Y was enhanced 9-, 6-, 9-, and 10-fold, respectively, by sulfinpyrazone compared with 4-fold for wild-type MRP2.
X
ABCC2 p.Trp1254Phe 11500505:116:91
status: NEW129 Membrane vesicles prepared from HEK293T cells expressing wild-type (WT-MRP2) and mutant W1254F-MRP2 were incubated with [3 H]E217betaG in the absence (open bars) and presence (solid and shaded bars) of 1 M LTC4 for 5 min as described under "Experimental Procedures."
X
ABCC2 p.Trp1254Phe 11500505:129:88
status: NEW133 B, membrane vesicles (8 g of protein) from cells expressing WT-MRP2 and mutants W1254F-MRP2 and W1254Y-MRP2 were incubated at 37 °C with 400 nM [3 H]E217betaG in transport buffer and other components for 5 min in the absence (open bars) or the presence of MTX (500 M, shaded bar; 1000 M, solid bar) as described under "Experimental Procedures."
X
ABCC2 p.Trp1254Phe 11500505:133:88
status: NEW139 However, LTC4 transport by MRP2 was also markedly reduced when Trp1254 was replaced with Phe but less so when it was replaced with Tyr.
X
ABCC2 p.Trp1254Phe 11500505:139:63
status: NEW141 The selective loss of LTC4 transport activity of the W1254F-MRP2 mutant was matched by the inability of the cysteinyl leukotriene to inhibit [3 H]E217betaG transport by this mutant, suggesting that loss of LTC4 transport is caused by a loss of binding of this substrate to the protein.
X
ABCC2 p.Trp1254Phe 11500505:141:53
status: NEW151 However, although [3 H]E217betaG transport by the MRP2- W1254F and MRP2-W1254Y mutants appeared unchanged despite their inability to transport MTX, transport of the conjugated estrogen was no longer inhibited by the antifolate agent.
X
ABCC2 p.Trp1254Phe 11500505:151:56
status: NEW156 Of the three MRP2 substrates examined in the present study, none were transported by the nonconservatively substituted W1254C and W1254A mutants, one was transported by the W1254F mutant, and two were transported by the W1254Y mutant.
X
ABCC2 p.Trp1254Phe 11500505:156:173
status: NEW159 Effect of sulfinpyrazone on [3 H]E217betaG uptake and [3 H]MTX uptake by wild-type and Trp1254 mutant MRP2 proteins. A, [3 H]E217betaG uptake was measured in the absence (open bars) and the presence (solid and shaded bars) of sulfinpyrazone (100 M) in membrane vesicles prepared from cells expressing wild-type (WT-MRP2) and mutant (W1254A, W1254C, W1254F, and W1254Y) MRP2 proteins as described under "Experimental Procedures."
X
ABCC2 p.Trp1254Phe 11500505:159:357
status: NEW